[{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPX-1009","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SPX-1009","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biotechnologies \/ Sapphire Biotech"},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SBI-183","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biotechnologies \/ Sapphire Biotech"}]

Find Clinical Drug Pipeline Developments & Deals by AXIM Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : AXIM intends to initiate animal studies to demonstrate the ability of SPX-1009 to suppress tumor growth and metastasis in a murine model of melanoma in a topical treatment.

                          Product Name : SPX-1009

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 26, 2021

                          Lead Product(s) : SPX-1009

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : United States Patent and Trademark Office has issued the Company a new Notice of Allowance for a patent on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and meta...

                          Product Name : SBI-183

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 22, 2020

                          Lead Product(s) : SBI-183

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Sapphire Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : Sapphire scientists have generated and tested over 90 analogs of SBI-183 and discovered that one analog, SPX-1009, was tenfold more potent than SBI-183 in suppressing tumor invasion and metastasis in vitro.

                          Product Name : SPX-1009

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 06, 2020

                          Lead Product(s) : SPX-1009

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Sapphire Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank